23andMe made a deal with a Spanish pharma company to develop a drug from its genetic research. The pharma company, Almirall, licensed an antibody identified by 23andMe to develop a dermatology treatment. This is 23andMe’s first drug development deal, opening up another use for the genetic data it has collected. (TechCrunch)

Oklahoma has settled with two opioid manufacturers for $8.75 million. The state settled a case against Endo Pharmaceuticals Inc. and Par Pharmaceutical. The case alleged the companies deceptively marketed opioids in the state. (Associated Press)

Eli Lilly plans to acquire Dermira for $1.1 billion. The biotech focuses on chronic skin conditions and currently has a promising drug in its pipeline to treat moderate-to-severe atopic dermatitis, a common form of eczema. (STAT)

Healthcare giants and startups are using tech for better primary care. From CVS and Walmart to startups like One Medical and Doctor on Demand, primary care is benefitting from virtual visits and expanded access. (CNBC)

Blueprint Medicines won its first drug approval from the Food and Drug Administration. The FDA approved its stomach cancer treatment, Ayvakit. The drug will be priced at $32,000 for a 30-day supply. (Reuters)